NAT10 and prostate carcinoma: At the same time, to explore the effects of castration on prostate cancer, VCaP cells were subjected to long-term treatment with enzalutamide at either low (2 μM) or high (20 μM) concentrations for at least four weeks, and the expression of NAT10, CDC6, and AR was measured.